iLife Discoveries (iLife) and OvaGene Oncology Inc. (OvaGene) have announced an alliance to introduce novel gene-based assays to improve patient care for Indian women battling ovarian, endometrial and cervical cancers.
The alliance furthers both companies’ mission to apply advanced molecular technologies to assist physicians treating women’s cancers.
The initial focus of the alliance will be to validate and commercialize novel assays to assist both medical and gynecologic oncologists in evaluating therapeutic alternatives. It is intended that, in time, an expanded panel of diagnostic and predictive services will be offered through the alliance.
Mr. Anand Gupta, Founder and Chairman of iLife stated, “It is indeed a great pleasure and a moment of pride for iLife to partner with OvaGene of USA. The gynecological cancer therapeutic panels developed by OvaGene are of great advantage and relevance towards providing therapeutic information and care selection strategy for the clinicians for the increasing numbers of gynecological related cancers in India and the Indian sub-continent.”
Frank J. Kiesner, Chairman and CEO of OvaGene commented, “The opportunity to work with iLife Discoveries will enable OvaGene’s gene-based assays to be represented by a network of 1200 trained sales professionals in India and the Indian sub-continent including markets of Sri-Lanka, Bangladesh, Pakistan and Nepal. Clearly, iLife is a scientific, medical, and commercialization leader within these markets. The alliance between OvaGene and iLife Discoveries will bring advanced
molecular innovation to the bedside of gynecologic cancer patients within these populous markets.”